Akebia Therapeutics (AKBA)
(Real Time Quote from BATS)
$1.42 USD
+0.11 (8.40%)
Updated Jul 16, 2024 03:55 PM ET
After-Market: $1.42 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
D Value B Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKBA 1.42 +0.11(8.40%)
Will AKBA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AKBA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKBA
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
AKBA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Other News for AKBA
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
Akebia Therapeutics Welcomes New CFO and Financial Strategist
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer